Pharma Digest

Lilly pays $6.3B upfront for sleep disorder-focused Centessa in latest neuroscience play Ambrosia scores $100M series B to take next-gen oral GLP-1 into the clinic Merck enlists antibody hunter Infinimmune for $838M biobucks pact

Mapping the Trillion-Gene Universe: The Startup That Wants to Teach AI the Language of Life Why Data Infrastructure Determines AI Success in Drug Discovery PhenoTips, Health Institutions Launch C$5.4M AI Genomic Medicine Initiative in Canada

AstraZeneca delivers dream result as phase 3 COPD hits breathe life into class rocked by flops Lilly further embraces Insilico’s AI tech, inking R&D collab worth up to $2.75B Merck dives into detailed phase 3 data showing PCSK9 pill easily outswims rivals

The Value of Prediction, and Cost of Success, in Drug Hunting Merck hands over $20M in IBD drug target deal with Flagship's Quotient The N-of-1 Revolution in Personalized Medicine

- Merck, girding for Keytruda cliff, flies toward promising CML asset with $6.7B Terns acquisition - OrbiMed-backed Pinnacle adds $89M series B to power oral peptide pipeline - Sarepta's big bet on Arrowhead's siRNA assets yields early data

Baylor College of Medicine Taps Nautilus’ Voyager for Cancer Proteomics The Download: OpenAI is building a fully automated researcher, and a psychedelic trial blind spot From scientist to bioinformatician: how AI coding tools dissolved the activation energy barrier

Lilly's triple-G bet lowers blood sugar, prompts 16.8% weight loss in phase 3 diabetes trial STAT+: A biotech turns to Apple Watch to study its Parkinson’s drug Which FDA Division Has the Most Stability As AI Tools Get Adopted Across the Agency?

With its first AI mod­el re­lease, Xaira tests scal­ing laws in vir­tu­al cells NVIDIA GTC 2026: Agentic AI Inflection Hits Healthcare and Life Sciences DOE Announces $293M Funding Opportunity as Genesis Mission Moves Toward Operational Phase

Pfizer's hotly tipped breast cancer prospect delivers phase 2 win Aspen's 1-year data for Parkinson's cell therapy plant seeds for phase 3 trial Crossbow hits $77M series B round to bankroll quiver of T-Bolts

Roche inks Nvidia deal to bolster AI factory, speed drug and diagnostic development Why most labs are not ready for AI: Cenevo shares what must change French AI Startup Building World Models Raises $1.03 billion

Structure touts 16% weight loss for aleniglipron as 'highest efficacy' for an oral GLP-1 yet R1 zooms out of stealth with $77.5M series A to advance chronic kidney disease treatment Danish biotech Gubra plots Roivant-like model to churn out new companies

Stop asking for an AI strategy: 3 questions clinical leaders should ask instead The Real Test for AI Diagnostics Isn’t Performance — It’s Clinical Adoption Real-World Evidence Meets Machine Learning: What It Takes to Future-Proof Evidence Generation

CytomX surges on positive data for ‘masked’ ADC in colorectal cancer Astellas walks away from $1.6B biobucks T-cell engager pact with CytomX after 6 years JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity — NeuroSense Therapeutics

Startup Waiv Spins Out of Owkin With $33M to Bring AI Precision to Cancer Decisions Artificial Intelligence and the Data Quality Problem No One Can Ignore Microsoft Enters Healthcare Chatbot Race with Copilot Health

GSK’s RSV vaccine wins broader FDA clearance Bimzelx tops Skyrizi in head-to-head psoriatic arthritis trial With FDA go ahead, a China biotech notches a first in cell therapy testing

An AI Driven Approach to Address the Non-Responder Gap in Radiopharmaceutical Therapy Agentic AI Swarms Degrade Decision-Making STAT+: AI agents are rapidly spreading in health care, but validation is lacking

Ultragenyx gene therapy hits co-primary endpoint in phase 3 rare disease study, teeing up potential win BridgeBio's muscle weakness data impress ahead of FDA filing Fledgling French biotech pens $128M deal for Kezar's preclinical protein degrader program

STAT+: New nonprofit launches with at least $500 million to modernize scientific process for AI era Bota/Enhe’s SAION AI push toward closed‑loop, machine‑protocol‑driven biomanufacturing Tailored Training Can Address Biopharma Skills Shortage

Regeneron's obesity drug shows Zepbound-like efficacy in phase 3 Tenacia builds $308M biobucks deal with Rapport to develop epilepsy drug in greater China $270M RNA Drug Spinout Targets Rare Genetic Cardiomyopathies

Smarter Filings, Smarter Factories Health AI startup to benefit from $1 billion funding round for Yann LeCun’s AMI Breakout Ventures launches $114M AI-focused fund

Vertex races to FDA after phase 3 kidney disease data impress analysts Servier Boosts Presence in Rare Cancers With $2.5B Acquisition of Day One Biopharma FDA reconsidering Capricor’s snubbed DMD cell therapy after 'lifting' rejection

CVS, Humana & More Are Turning to Google’s AI Models AI Startups Are Tying Fees to Completed Tasks. Will Hospitals Buy In? For Anthropic, Pragmatism Is the More Trustworthy Position

FDA issues speedy approval to J&J’s Tecvayli-Darzalex combo Xenon phase 3 epilepsy readout 'blows away' expectations, stock soars BMS builds momentum for CELMoD drug after improving myeloma PFS in phase 3

Future of Health Tech: From Structured Data to Scalable AI Capturing the Vibe at ViVE 2026, Healthcare Executives Share Insights on Medication Adherence and Implementing AI Privacy Expectations in Consumer AI Tools: How Patient Use of ChatGPT Health and Claude Differs From HIPAA-Regulated Care

Merck KGaA drops pipeline assets from SpringWorks buyout, Hengrui licensing deal FDA to end 9-month advisory committee drought with April review of AstraZeneca’s oral SERD, Truqap Roche pumps $480M into South Korea biopharma industry to establish global trial 'ecosystem'